CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Hangzhou Berry Genomics, a subsidiary of Berry Genomics, has received premarket clearance from the Chinese Food and Drug Administration for the NextSeq CN500, a high-throughput sequencing instrument developed with Illumina to meet Chinese clinical needs. Hangzhou Berry Genomics also received premarket clearance for its noninvasive prenatal testing detection kit for trisomies 13, 18, and 21.
Read More »